Guanhao Biotech Co Ltd Net Asset Quality Index
Guanhao Biotech Co Ltd net asset quality index. Guanhao Biotech Co Ltd (300238) has a Net Asset Quality Index of 62.9% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥787.22 Million minus total liabilities of CN¥292.32 Million yields net assets of CN¥494.91 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check 300238 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Guanhao Biotech Co Ltd (2007–2025)
Net asset quality index of Guanhao Biotech Co Ltd from 2007 to 2025. This chart shows how Guanhao Biotech Co Ltd's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the index stands at 62.9%, representing net assets of CN¥494.91 Million against total assets of CN¥787.22 Million CNY. See Guanhao Biotech Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Guanhao Biotech Co Ltd Net Asset Quality Index by Year (2007–2025)
Guanhao Biotech Co Ltd net asset quality index by year from 2007 to 2025. The table below presents the year-by-year Net Asset Quality Index for Guanhao Biotech Co Ltd from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market value of Guanhao Biotech Co Ltd.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 62.7% | CN¥506.03 Million | CN¥806.53 Million | CN¥300.50 Million | ▲ +0.8 pp |
| 2024 | 62.0% | CN¥467.59 Million | CN¥754.40 Million | CN¥286.81 Million | ▼ -5.3 pp |
| 2023 | 67.2% | CN¥456.26 Million | CN¥678.59 Million | CN¥222.33 Million | ▲ +2.9 pp |
| 2022 | 64.3% | CN¥430.88 Million | CN¥670.21 Million | CN¥239.33 Million | ▼ -3.8 pp |
| 2021 | 68.1% | CN¥748.16 Million | CN¥1.10 Billion | CN¥350.58 Million | ▲ +4.9 pp |
| 2020 | 63.2% | CN¥716.66 Million | CN¥1.13 Billion | CN¥418.07 Million | ▲ +1.9 pp |
| 2019 | 61.3% | CN¥704.14 Million | CN¥1.15 Billion | CN¥445.21 Million | ▼ -9.2 pp |
| 2018 | 70.5% | CN¥1.16 Billion | CN¥1.64 Billion | CN¥483.57 Million | ▼ -0.1 pp |
| 2017 | 70.6% | CN¥1.21 Billion | CN¥1.72 Billion | CN¥505.25 Million | ▼ -15.7 pp |
| 2016 | 86.3% | CN¥1.46 Billion | CN¥1.69 Billion | CN¥230.93 Million | ▲ +9.4 pp |
| 2015 | 76.9% | CN¥620.62 Million | CN¥807.02 Million | CN¥186.41 Million | ▼ -8.9 pp |
| 2014 | 85.8% | CN¥531.61 Million | CN¥619.54 Million | CN¥87.92 Million | ▼ -1.2 pp |
| 2013 | 87.0% | CN¥498.16 Million | CN¥572.52 Million | CN¥74.36 Million | ▲ +3.2 pp |
| 2012 | 83.8% | CN¥454.11 Million | CN¥541.99 Million | CN¥87.88 Million | ▼ -3.5 pp |
| 2011 | 87.2% | CN¥432.79 Million | CN¥496.06 Million | CN¥63.27 Million | ▲ +25.8 pp |
| 2010 | 61.4% | CN¥144.99 Million | CN¥236.02 Million | CN¥91.03 Million | ▼ -1.5 pp |
| 2009 | 62.9% | CN¥76.95 Million | CN¥122.30 Million | CN¥45.34 Million | ▲ +3.1 pp |
| 2008 | 59.9% | CN¥37.01 Million | CN¥61.82 Million | CN¥24.81 Million | ▲ +9.1 pp |
| 2007 | 50.8% | CN¥20.67 Million | CN¥40.70 Million | CN¥20.03 Million | — |